STING Agonists as Cancer Therapeutics

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Lack of antigen presentation and type I interferon signaling are biomarkers for non-T-cell-inflamed tumors and clinical progression in cancer immunotherapy.
• The cGAS/stimulator of interferon genes (STING) pathway, a cytosolic DNA-sensing pathway, is implicated in anti-tumor immune responses, including type I interferon activation and modulation of tumor vasculature.
• The STING pathway also supports adaptive immunity through tertiary lymphoid structure development.

Purpose of the Study:

• To review the latest developments in STING-targeted cancer therapies.
• To provide an update on the clinical development and application of STING agonists.
• To explore the potential of STING agonists in combination with other immunotherapies.

Main Methods:

• Review of pre-clinical studies on the STING pathway in cancer.
• Analysis of clinical trial data for STING agonists.
• Evaluation of novel delivery systems for STING agonists.

Main Results:

• First-generation intra-tumor delivered cyclic dinucleotides showed safety but limited systemic activity.
• Development of more potent and selective STING agonists is ongoing.
• Novel delivery systems aim for sustained inflammation in the tumor microenvironment.

Conclusions:

• STING agonists hold potential to augment response rates to current immunotherapies.
• STING-targeted therapies may overcome acquired resistance to cancer immunotherapy.
• Combination strategies involving STING agonists are being investigated to improve clinical outcomes.